

Published by the **American Association for the Advancement of Science (AAAS)**, *Science* serves its readers as a forum for the presentation and discussion of important issues related to the advancement of science, including the presentation of minority or conflicting points of view, rather than by publishing only material on which a consensus has been reached. Accordingly, all articles published in *Science*—including editorials, news and comment, and book reviews—are signed and reflect the individual views of the authors and not official points of view adopted by the AAAS or the institutions with which the authors are affiliated.

The American Association for the Advancement of Science was founded in 1848 and incorporated in 1874. Its objectives are to further the work of scientists, to facilitate cooperation among them, to foster scientific freedom and responsibility, to improve the effectiveness of science in the promotion of human welfare, to advance education in science, and to increase public understanding and appreciation of the importance and promise of the methods of science in human progress.

#### Membership/Circulation

**Director:** Michael Spinella  
**Deputy Director:** Marlene Zendell  
**Member Services:** Rebecca Dickerson, *Manager*; Mary Curry, *Supervisor*; Pat Butler, Helen Williams, Laurie Baker, *Representatives*  
**Marketing:** Dee Valencia, *Manager*; Jane Pennington, *Europe Manager*; Hilary Baar, *Associate*; Angela Mumeka, *Coordinator*  
**Research:** Renuka Chander, *Manager*  
**Business and Finance:** Jacquelyn Roberts, *Manager*; Robert Smariga, *Assistant Manager*  
**Administrative Assistant:** Nina Araujo de Kobes  
**Science Member Services**  
 Marion, Ohio: 800-347-6969;  
 Washington, DC: 202-326-6417  
**Other AAAS Programs:** 202-326-6400

#### Advertising and Finance

**Associate Publisher:** Beth Rosner  
**Advertising Sales Manager:** Susan A. Meredith  
**Recruitment Advertising Manager:** Janis Crowley  
**Advertising Business Manager:** Deborah Rivera-Wienhold  
**Finance:** Randy Yi, *Senior Analyst*; Shawn Williams, *Analyst*  
**Marketing:** John Meyers, *Manager*; Allison Pritchard, *Associate*  
**Traffic Manager:** Tina Turano  
**Recruitment:** Terri Seiter, *Assistant Manager*; Debbie Cummings, Celeste Wakefield, Rachael Wilson, *Sales Reprints Manager*; Corrine Harris  
**Permissions Manager:** Arlene Ennis  
**Sales Associate:** Carol Maddox

**PRODUCT ADVERTISING SALES: East Coast/E. Canada:** Richard Teeling, 201-904-9774, FAX 201-904-9701 • **Midwest/Southeast:** Elizabeth Mosko, 312-665-1150, FAX 312-665-2129 • **West Coast/W. Canada:** Neil Boylan, 415-673-9265, FAX 415-673-9267 • **UK, Scandinavia, France, Italy, Belgium, Netherlands:** Andrew Davies, (44) 457-838-519, FAX (44) 457-838-898 • **Germany/Switzerland/Austria:** Tracey Peers, (44) 270-760-108, FAX (44) 270-759-597 • **Japan:** Mashy Yoshikawa, (3) 3235-5961, FAX (3) 3235-5852  
**RECRUITMENT ADVERTISING SALES: US:** 202-326-6555, FAX 202-682-0816 • **Europe:** Gordon Clark, (44) 81539-5211, FAX (44) 0223-302068 • **Australia/New Zealand:** Keith Sandell, (61) 02-922-2977, FAX (61) 02-922-1100  
 Send materials to *Science* Advertising, 1333 H Street, NW, Washington, DC 20005.

**Information for Contributors** appears on pages 37–39 of the 7 January 1994 issue. Editorial correspondence, including requests for permission to reprint and reprint orders, should be sent to 1333 H Street, NW, Washington, DC 20005.  
**Internet addresses:** science\_editors@aaas.org (for general editorial queries); science\_letters@aaas.org (for letters to the editor); science\_reviews@aaas.org (for returning manuscript reviews); membership@aaas.org (for member services); science\_classifieds@aaas.org (for submitting classified advertisements)

## Tagging “Infiltrators”

It is an unwelcome sign of the times that Bill Wattenburg’s Policy Forum “Fluorescent barriers to infiltration” appeared in *Science* (26 Aug., p. 1184), instead of in a military ordnance journal. Wattenburg proposes to block illegal immigration across the U.S.-Mexico border by aerial dusting with fluorescent chemicals, thereby tagging would-be “infiltrators” into San Diego. The danger in such a scheme is less in its dubious practical outcome than in its invitation to scientists to collaborate with xenophobia. Those of us who find human tagging distasteful, whether with fluorescent dyes or yellow stars, must question his premises.

Immigrants, legal or otherwise, have long been a convenient scapegoat for troubled economies. California’s fiscal crisis stems from long-term decline in manufacturing, politically expedient tax cuts, and an overheated real estate market. The widespread belief, echoed by Wattenburg, that illegal immigrants are a drain on the economy and cause unemployment among U.S. workers has been effectively challenged by demographers. Politicians from David Duke to California Governor Pete Wilson obscure these realities by targeting undocumented workers, invariably those with dark skin. One product of this movement, the “Save Our State” proposition on the November ballot, would deny schooling and basic medical care to California’s undocumented immigrants.

Experience suggests that high-tech gadgets are no match for desperate and determined people. During the Vietnam War, the “Jason” group of elite scientists arranged for 20,000 sensors of various types to be dropped on the Ho Chi Minh Trail to interdict Northern “infiltration.” This “McNamara Line” was notoriously ineffective; reportedly, the North Vietnamese decoyed “people sniffers” by hanging bags of urine in the trees. We can expect similar resourcefulness from Mexican immigrants, who after all are not criminals, but impoverished workers seeking a better life for their children. The real impact of Wattenburg’s proposal would be to lend credibility to anti-immigrant hysteria, at present the leading edge of “respectable” racism in this country.

**Miriam Golomb**

*Division of Biological Sciences,  
 University of Missouri,  
 Columbia, MO 65211, USA*

## Environmental Estrogens

The Environmental Protection Agency (EPA) was pleased to read “Environmental estrogens stir debate” by Richard Stone (*News & Comment*, 15 July, p. 308), where it was stated that in “the debate over hormone-modulating pollutants,” EPA has increased its emphasis “on the noncancer effects of the chemicals it regulates.” This approach is characterized as “a fresh concern for EPA, which in the past has crafted regulations based mainly on chemical carcinogenicity.” While EPA has indeed often emphasized chemical carcinogenicity, noncancer health effects are also considered in most of EPA’s regulatory actions, and some regulations are based solely on effects other than cancer.

All of the statutes under which EPA regulates provide authority to regulate for noncancer health effects. For example, the Clean Air Act designates six criteria pollutants (lead, particulate matter, ozone, nitrogen oxides, sulfur oxides, and carbon monoxide). Under this act, EPA must set a National Ambient Air Quality Standard (NAAQS) for each criteria pollutant for the entire United States “which in the judgment of [EPA], based on such criteria and allowing an adequate margin of safety, [is] requisite to protect the public health” (1).


The NAAQs are based on a range of observed health effects which include respiratory effects, cognitive and neurobehavioral effects, reproductive effects, and death. None of the ambient air quality standards are based on carcinogenicity. In addition, the Clean Air Act lists 189 hazardous air pollutants that are subject to National Emission Standards for Hazardous Air Pollutants. A large proportion of these pollutants are not considered to be possible human carcinogens and are instead regulated on the basis of noncancer effects.

In addition, health effects testing authorities under the Toxic Substances Control Act and the Federal Insecticide, Fungicide and Rodenticide Act require testing of industrial chemicals and pesticides for multiple health endpoints, including mutagenesis, teratogenesis, behavioral disorders, and carcinogenesis. EPA uses this and other information in its ongoing evaluation of noncancer toxicity and regularly sets reference doses (RfDs), which are threshold levels of safe exposure for noncancer effects. These are routinely used in regulatory decisions.

## Opinion

Matrix Assisted Laser Desorption/Ionization (MALDI) has brought remarkable improvements to the analysis of biomolecules. Time-of-Flight mass spectrometers using MALDI show extraordinary sensitivity and good mass accuracy for molecules otherwise intractable to mass spectrometry.

Maldi has primarily been used to determine molecular weights. However, it has recently been applied to gain structural information about sensitive biomolecules. Some glycoproteins for example show extensive metastable decay of the molecular ion. Comparing the mass spectrum in the linear time of flight mode with the spectrum in the reflector mode reveals the mass of an oligosaccharide moiety being lost. Remarkably, this can be achieved even with fragments of around 1000 Dalton lost from a glycoprotein with molecular mass of 80 000 Dalton.



The measurement of metastable ions in MALDI reveals important sequence information for biopolymers.

The VISION 2000 system has been designed to be easily adapted to new applications. This has enabled Finnigan MAT to immediately make available a system that can cover these new applications by operating in different modes depending on the type of analysis required.

The Post Source Decay (PSD) of metastable ions created under MALDI conditions reveals important biopolymer sequence information. The VISION 2000 can be switched from reflector mode to PSD mode under full data system control, leaving all necessary voltage changes in the system transparent to the user. Sequencing of a peptide in PSD mode becomes an easy task.



Germany: (+49)421/5493-0, Fax 5493-396  
U.K.: (+44)442/233555, Fax 233666  
USA: (+1)408/433-4800, Fax 433 4823  
Japan: (+81)03/372 3001, Fax 3372 7051

The OPINION column features technical tips & preliminary information relating to instruments designed & built at Finnigan MAT GmbH, Bremen, Germany.

Finally, addressing chemical estrogenicity is not a departure from past EPA practice. In our efforts to protect public health, we consider results from many types of tests and studies examining the full range of health endpoints before making regulatory decisions. As our understanding of the effects of chemicals on human health and the environment evolves, our regulatory decisions will continue to incorporate the latest science. Thank you for your efforts to inform the public understanding of these critical issues.

**David Gardiner**

Assistant Administrator,

U.S. Environmental Protection Agency,  
Washington, DC 20460, USA

### References

1. Clean Air Act, Section 109(b)(1).

Stone's article "Environmental estrogens stir debate" is well researched and well balanced. The differences of opinion are justified, but in some cases persuasive logic can be used to reach opposite conclusions. The "two points . . . arguing against a demonstrable link between hormone-modulating pollutants and human health effects," when examined closely, actually support the possibility of human health effects.

1) Basic pharmacology seldom can be counted on to simply "add up." The "very weak [environmental] estrogens" such as polychlorinated biphenyls (PCBs), with 100- to 10,000-fold lower affinities for estrogen receptors, are present in human blood at about 2 to 8 nanograms (ng) per milliliter (ml); estrogen occurs in cycles in human female blood in amounts of between 0.03 and 0.50 ng/ml, and most of this is bound to plasma proteins or conjugated to disarming groups, or both. Along with the PCBs are found DDE (the principal metabolite of DDT), mirex, methoxychlor, phthalates, and other pesticides and plasticizers in concentrations at least equivalent to those of endogenous estrogens. If the lesser binding and greater membrane transport of the weak estrogens are factored in, the pharmacology begins to add up.

2) The acid-base argument is the more frightening possibility. Certainly, if a precise combination of estrogenic and antiestrogenic chemicals is present, "the net effect may be zero" (if one ignores the other disrupting effects cited by Earl Gray and Richard Peterson). However, dioxin is (justifiably) one of the most targeted environmental contaminants, and progress has been made in attenuating environmental concentrations. As the balance which may have been in place shifts, estrogenic and other subtle toxicities may be unmasked. This is amply illustrated in the comparison

of Mary Wolff *et al.*'s study of the association of DDE with breast cancer (1) with Nancy Krieger *et al.*'s study (2), which did not support the association. The exposures Krieger *et al.* found were from before 1970 and included higher DDT concentrations than those in the more recent exposures found by Wolff *et al.* (G. Taubes, News & Comment, 22 Apr., p. 499). Before 1970, however, we were only becoming aware of dioxin toxicity and could not even detect it near the concentrations of today's regulations. Therefore, products such as 2,4,5-T, hexachlorophene, and pentachlorophenol (which were banned before Wolff *et al.*'s exposures were found) contained higher concentrations of dioxin. Dioxin is more potent as an antiestrogen than DDE is as an estrogen; therefore, the lack of association between DDE burdens and breast cancer before 1970 and the positive association after 1985 should, perhaps, have been expected. The below-normal incidence of breast cancer and endometrial cancer in the (dioxin-exposed) population near Seveso, Italy, was expected (3).

This is a small sample of the complicating factors among the environmental hormone disrupters and the endogenous hormones and neurotransmitters. Even if, as Stephen Safe has stated, "the [PCB] problem is under control" (R. Stone, Research News, 14 Feb. 1992, p. 798), the "other environmental problems" Safe referred to in 1992 all involve interactions. If we can successfully describe and quantify some of these interactions so that we can successfully predict the net biological effects of even a few simple mixtures, then the risk assessment of environmental mixtures, and thus the health and welfare of humans and wildlife, will have been well served.

**Larry G. Hansen**

Department of Veterinary Biosciences,  
University of Illinois,  
2001 South Lincoln Avenue,  
Urbana, IL 61801, USA

**Heiko T. Jansen**

Department of Cell Biology,  
Neurobiology and Anatomy,  
University of Cincinnati,  
231 Bethesda Avenue,  
Cincinnati, OH 45267-0521, USA

### References

1. M. S. Wolff *et al.*, *J. Natl. Cancer Inst.* **85**, 648 (1993).
2. N. Krieger *et al.*, *ibid.* **86**, 589 (1994).
3. M. Holloway, *Sci. Am.* **270**, 25 (January 1994).

Stone reports on two recent epidemiologic studies of whether DDT exposure relates to a risk of breast cancer. In the first of these studies (1), one of us (M.S.W.), with Paolo Toniolo at New York University Medical Center and others, found strong evidence

for an association between the body burden of DDE and breast cancer risk in a population of primarily Caucasian women. For women with the highest body burdens of DDE, the risk of breast cancer was found to be four times higher than for those with the lowest burdens. In the second study (2) by Nancy Krieger and her colleagues at the Kaiser Foundation Research Institute, no association was found between DDT and breast cancer when women of all races were examined together. However, a positive association (although not statistically significant) was observed between DDT and breast cancer risk in Caucasian and African-American women. Among Asian women there was no evidence of an association.

There are several possible mechanisms by which DDT may increase risk of breast cancer. Hormonal modulation (estrogenicity and antiestrogenicity) is only one possibility. Another is induction of cytochrome P450 enzymes. These mechanisms may act independently or in concert with one another. Moreover, whatever the mechanisms of action, the carcinogenic potency of DDT and its metabolites may be enhanced by the persistence of these compounds in the human body.

To determine whether the apparent association between DDT and breast cancer risk is real, further epidemiologic investigations as well as complementary mechanistic studies must be carried out. The ultimate hope is that this research may identify a preventable environmental cause of breast cancer in women.

Mary S. Wolff

Philip J. Landrigan

Mount Sinai Medical Center,  
One Gustave L. Levy Place,  
New York, NY 10029-6574, USA

#### References

1. M. S. Wolff *et al.*, *J. Natl. Cancer Inst.* **85**, 648 (1993).
2. N. Krieger *et al.*, *ibid.* **86**: 589 (1994).

### Genetic Testing and Insurance Costs

In his letter about genetic testing and the costs of insurance (9 Sept., p. 1509), J. Alexander Lowden argues that "If . . . only the applicant [can] know his or her risk and may legally conceal it from the insurer, then insurance will become too expensive for all but those who know they will succumb at an early age." The argument is specious. The cost of insuring individuals who have genetic diseases has been included in insurance costs based on actuarial tables when there was no genetic testing, and the deaths due to inherited disease were part of the age-distributed probability of death due to random-

ly experienced causes. The insurance companies did not go broke during that period, as Lowden fears could happen in the future.

If one of the insured in that distribution knows that he or she will die of a certain disease, but the insurance company doesn't, little will have been changed for the insurance company. Lowden might fear that individuals who know they will die of a certain disease, perhaps prematurely, will stock up on insurance to better provide for their heirs. However, the levels of insurance individuals buy are dictated by affordability.

Even if the relatively small fraction of the population with heritable diseases were to double the amount of life insurance they buy, there would still be a random element to the payout periods. The cause of death might be predictable, but the age of death is not, within broad limits. By excluding people who have been diagnosed as having a genetic disease, the insurance companies would shift the mean age of death in their actuarial distributions to a higher age. This will defer benefit payments and help short-term profits. Long-term profits should not be affected significantly, as most of "the rest of us [with] perfect genes" will either collect their annuities or die while insured.

S. J. Deitchman

3606 Stewart Drive,  
Chevy Chase, MD 20815, USA

### Children's Vaccine Initiative

The special *Science* issue "Frontiers in medicine: vaccines" (2 Sept. 1994) is an excellent and comprehensive report focusing on the high cost-effectiveness of vaccines and the need for new initiatives to bring their benefits to the children who need them most.

The News reports emphasize the need for intensified efforts to bring new research ideas to fruition in the form of vaccines against the most important diseases of the developing world, ensuring all the while that these vaccines will not be priced so high as to be unreachable for most children.

As Ann Gibbons points out (News, 2 Sept., p. 1376), the Children's Vaccine Initiative (CVI) has been slow to gain momentum. The recent reorganization in the World Health Organization (WHO) to centralize vaccine activities in the Global Programme for Vaccines and Immunization will now provide the strong leadership necessary to move ahead. The three units of the Global Programme for Vaccines and Immunization—Vaccine Research and Development, Vaccine Supply and Quality, and the Expanded Programme on Immunization—can address barriers to delivery of old vaccines

TO ANYONE WHO THINKS THAT CARBOHYDRATE SEPARATION MIGHT HAVE REACHED ITS PEAK.....  
WELL IT HASN'T

**Signal™ fluorescent labelling and GlycoSep™ HPLC columns allow cost-effective, quantitative and preparative profiling of charged and neutral glycans.**

**Signal™ Fluorescent Labelling**  
Signal™ is a simple, convenient method of fluorescent labelling a glycan pool. The technique utilizes 2-aminobenzamide (2-AB) in a validated, 2 step procedure that labels glycans efficiently (>85%) and non-selectively at the reducing terminus.

#### GlycoSep™ High Resolution Glycan Profiling

GlycoSep™ is an HPLC based kit that allows 2 dimensional profiling of 2-AB labelled glycans, providing reproducible, quantitative results. As no high pH conditions are used, structural integrity is assured and sample isolation and work-up is easy.

To find out how Signal™ and GlycoSep™ can extend your carbohydrate-related research, call us today.

**800-722-2597**



Oxford GlycoSystems Inc. Cross Island Plaza, 133-33 Brookville Boulevard, Rosedale, New York 11422 U.S.A.